Ivo G Schoots1, Keren Zaccai2, Myriam G Hunink3, Paul C M S Verhagen2. 1. Department of Radiology and Nuclear Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands. Electronic address: i.schoots@erasmusmc.nl. 2. Department of Urology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands. 3. Department of Radiology and Nuclear Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands; Harvard School of Public Health, Harvard University, Department of Health Policy and Management, Boston, Massachusetts.
Abstract
PURPOSE: We systematically evaluated the Bosniak classification system with malignancy rates of each Bosniak category, and assessed the effectiveness related to surgical treatment and oncologic outcome based on recurrence and/or metastasis. MATERIALS AND METHODS: In a systematic review according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) criteria, we selected 39 publications for inclusion in this analysis and categorized them into 1) surgical cohorts-all cysts treated surgically and 2) radiological cohorts-cysts with surgical treatment or radiological followup. RESULTS: A total of 3,036 complex renal cysts were categorized into Bosniak II, IIF, III and IV. In surgical and radiological cohorts pooled estimates showed a malignancy prevalence of 0.51 (0.44, 0.58) in Bosniak III and 0.89 (0.83, 0.92) in Bosniak IV cysts, respectively. Stable Bosniak IIF cysts showed a malignancy rate of less than 1% during radiological followup (surveillance). Bosniak IIF cysts, which showed reclassification to the Bosniak III/IV category during radiological followup (12%), showed malignancy in 85%, comparable to Bosniak IV cysts. The estimated surgical number needed to treat to avoid metastatic disease of Bosniak III and IV cysts was 140 and 40, respectively. CONCLUSIONS: The effectiveness of the Bosniak classification system for complex renal cysts was high in categories II, IIF and IV, but low in category III, and 49% of Bosniak III cysts was overtreated because of a benign outcome. This surgical overtreatment combined with the excellent outcome for Bosniak III cysts may suggest that surveillance is a rational alternative to surgery. This will require further study to assess whether surveillance of Bosniak III cysts will prove safe.
PURPOSE: We systematically evaluated the Bosniak classification system with malignancy rates of each Bosniak category, and assessed the effectiveness related to surgical treatment and oncologic outcome based on recurrence and/or metastasis. MATERIALS AND METHODS: In a systematic review according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) criteria, we selected 39 publications for inclusion in this analysis and categorized them into 1) surgical cohorts-all cysts treated surgically and 2) radiological cohorts-cysts with surgical treatment or radiological followup. RESULTS: A total of 3,036 complex renal cysts were categorized into Bosniak II, IIF, III and IV. In surgical and radiological cohorts pooled estimates showed a malignancy prevalence of 0.51 (0.44, 0.58) in Bosniak III and 0.89 (0.83, 0.92) in Bosniak IV cysts, respectively. Stable Bosniak IIF cysts showed a malignancy rate of less than 1% during radiological followup (surveillance). Bosniak IIF cysts, which showed reclassification to the Bosniak III/IV category during radiological followup (12%), showed malignancy in 85%, comparable to Bosniak IV cysts. The estimated surgical number needed to treat to avoid metastatic disease of Bosniak III and IV cysts was 140 and 40, respectively. CONCLUSIONS: The effectiveness of the Bosniak classification system for complex renal cysts was high in categories II, IIF and IV, but low in category III, and 49% of Bosniak III cysts was overtreated because of a benign outcome. This surgical overtreatment combined with the excellent outcome for Bosniak III cysts may suggest that surveillance is a rational alternative to surgery. This will require further study to assess whether surveillance of Bosniak III cysts will prove safe.
Authors: Matthew S Davenport; Eric M Hu; Andrew Zhang; Atul B Shinagare; Andrew D Smith; Ivan Pedrosa; Samuel D Kaffenberger; Stuart G Silverman Journal: Abdom Radiol (NY) Date: 2019-04
Authors: Anas M Saad; Mohamed M Gad; Muneer J Al-Husseini; Inas A Ruhban; Mohamad Bassam Sonbol; Thai H Ho Journal: Clin Genitourin Cancer Date: 2018-10-11 Impact factor: 2.872
Authors: Andrew W Silagy; Alejandro Sanchez; Brandon J Manley; Karim Bensalah; Axel Bex; Jose A Karam; Börje Ljungberg; Brian Shuch; A Ari Hakimi Journal: Eur Urol Focus Date: 2019-04-28
Authors: Mahyar Kashan; Mazyar Ghanaat; Andreas M Hötker; Cihan Duzgol; Alejandro Sanchez; Renzo G DiNatale; Kyle A Blum; Maria F Becerra; Brandon J Manley; Jozefina Casuscelli; Michael Chiok; Jonathan A Coleman; Paul Russo; Satish K Tickoo; Oguz Akin; A Ari Hakimi Journal: J Urol Date: 2018-03-01 Impact factor: 7.450
Authors: Nityanand Miskin; Lei Qin; Shanna A Matalon; Sree H Tirumani; Francesco Alessandrino; Stuart G Silverman; Atul B Shinagare Journal: Abdom Radiol (NY) Date: 2020-07-01
Authors: Stuart G Silverman; Ivan Pedrosa; James H Ellis; Nicole M Hindman; Nicola Schieda; Andrew D Smith; Erick M Remer; Atul B Shinagare; Nicole E Curci; Steven S Raman; Shane A Wells; Samuel D Kaffenberger; Zhen J Wang; Hersh Chandarana; Matthew S Davenport Journal: Radiology Date: 2019-06-18 Impact factor: 11.105
Authors: David Castañeda-Millán; Darwin Barros-Valderrama; Diego Camacho-Nieto; Carlos A Riveros; Juan Alzate-Granados; Javier Salgado-Tovar; Wilfredo Donoso-Donoso Journal: Cureus Date: 2019-11-29